Literature DB >> 21853342

Clinical value of Tiam1-Rac1 signaling in primary gallbladder carcinoma.

Xilin Du1, Shengzhi Wang, Jianguo Lu, Qing Wang, Nuan Song, Tao Yang, Rui Dong, Li Zang, Yuan Yang, Tao Wu, Chengguo Wang.   

Abstract

Tiam1-Rac1 signaling plays an important role in the migration, invasion and metastasis of tumor cells. The aim of the present study was to clarify the clinical value of Tiam1 and Rac1 expression in primary gallbladder carcinoma (PGC). Eighty-six PGC tissues were evaluated by immunohistochemistry for Tiam1 and Rac1 expression. The association of Tiam1 and Rac1 expression with clinicopathological characteristics and the univariate survival analysis for the influence of Tiam1 and Rac1 expression on the overall survival were analyzed. Tiam1 and Rac1 immunoreactivities were observed in 72 (83.7%) and 68 (79.1%) of the 86 PGC cases, but not in the non-neoplastic gallbladder tissues, respectively. The tumors with the positive expression of Tiam1 and Rac1 more frequently showed lymph node metastasis (P = 0.01 and 0.008), lymphovascular invasion (P = 0.009 and 0.01) and recurrence (both P = 0.01), respectively. In addition, the tumors with the positive expression of Tiam1 and Rac1 significantly tended to show deeper invasion depth (P = 0.007 and 0.005) and higher TNM stage (both P = 0.005). The Kaplan-Meier survival curves demonstrated that patients with the positive expression of Tiam1 and Rac1 had a significantly shorter survival time than those patients with their negative expression (both P = 0.01). Multivariate analysis revealed that the positive expression of Tiam1 (P = 0.02) and Rac1 (P = 0.02), as well as TNM stage (P = 0.04), to be independently associated with a poor prognosis of patients with PGC. The data from this study suggest for the first time that Tiam1 and Rac1 are frequently expressed in PGC and are associated with decreased survival of the patients. Therefore, Tiam1 and Rac1 expressions may be independent predictors for the poor prognosis in patients with PGC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21853342     DOI: 10.1007/s12032-011-0046-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.

Authors:  Yuan Gao; J Bradley Dickerson; Fukun Guo; Jie Zheng; Yi Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

2.  Prognostic value of Tiam1 and Rac1 overexpression in nasopharyngeal carcinoma.

Authors:  Yan Qi; Bo Huang; Linlin Yu; Qi Wang; Guiping Lan; Qiuhang Zhang
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2009-06-09       Impact factor: 1.538

3.  Parametric survival models for predicting the benefit of adjuvant chemoradiotherapy in gallbladder cancer.

Authors:  Samuel J Wang; Jayashree Kalpathy-Cramer; Jong Sung Kim; C David Fuller; Charles R Thomas
Journal:  AMIA Annu Symp Proc       Date:  2010-11-13

Review 4.  Carcinoma of the gallbladder.

Authors:  Sanjeev Misra; Arun Chaturvedi; Naresh C Misra; Indra D Sharma
Journal:  Lancet Oncol       Date:  2003-03       Impact factor: 41.316

5.  Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression.

Authors:  R Engers; E Springer; F Michiels; J G Collard; H E Gabbert
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

6.  Rac1 mediates sex difference in cardiac tumor necrosis factor-alpha expression via NADPH oxidase-ERK1/2/p38 MAPK pathway in endotoxemia.

Authors:  Huaqing Zhu; Limei Shan; Tianqing Peng
Journal:  J Mol Cell Cardiol       Date:  2009-05-18       Impact factor: 5.000

7.  Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation.

Authors:  Zobeida Cruz-Monserrate; Kathleen L O'Connor
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

8.  Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.

Authors:  K Strumane; T Rygiel; M van der Valk; J G Collard
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-01       Impact factor: 4.553

9.  CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.

Authors:  Patrick A Singleton; Ravi Salgia; Liliana Moreno-Vinasco; Jaideep Moitra; Saad Sammani; Tamara Mirzapoiazova; Joe G N Garcia
Journal:  J Biol Chem       Date:  2007-08-16       Impact factor: 5.157

10.  Antisense Tiam1 down-regulates the invasiveness of 95D cells in vitro.

Authors:  Min Hou; Li Tan; Xia Wang; Yun-Song Zhu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2004-08       Impact factor: 3.848

View more
  11 in total

1.  Expression of microRNA-10a, microRNA-342-3p and their predicted target gene TIAM1 in extranodal NK/T-cell lymphoma, nasal type.

Authors:  Haobo Huang; Liping Fan; Rong Zhan; Shunquan Wu; Wenyan Niu
Journal:  Oncol Lett       Date:  2015-10-27       Impact factor: 2.967

2.  Clinical implication of Tiam1 overexpression in the prognosis of patients with serous ovarian carcinoma.

Authors:  Huiwen Li; Xuelian Cui; Dingbao Chen; Yang Yang; Junjie Piao; Zhenhua Lin; Guanghai Yan; Danhua Shen
Journal:  Oncol Lett       Date:  2016-09-05       Impact factor: 2.967

3.  Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinin-induced cell cycle arrest and inhibited cell migration by suppressing NFκB activity.

Authors:  Peng Han; Ying Luan; Yanlong Liu; Zhiwei Yu; Jingwen Li; Zicheng Sun; Gang Chen; Binbin Cui
Journal:  Mol Cell Biochem       Date:  2013-04-05       Impact factor: 3.396

4.  IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer.

Authors:  Sonja M Kessler; Eva Lederer; Stephan Laggai; Nicole Golob-Schwarzl; Kevan Hosseini; Johannes Petzold; Caroline Schweiger; Robert Reihs; Marlen Keil; Jens Hoffmann; Christian Mayr; Tobias Kiesslich; Martin Pichler; Kyung Sik Kim; Hyungjin Rhee; Young Nyun Park; Sigurd Lax; Peter Obrist; Alexandra K Kiemer; Johannes Haybaeck
Journal:  Oncotarget       Date:  2017-09-21

Review 5.  Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis.

Authors:  Shu Lou; Penglai Wang; Jianrong Yang; Junqing Ma; Chao Liu; Meng Zhou
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

Review 6.  High Tiam1 expression predicts positive lymphatic metastasis and worse survival in patients with malignant solid tumors: a systematic review and meta-analysis.

Authors:  Caixia Yang; Chenlin Ma; Yingchun Li; Peng Mo; Yusheng Yang
Journal:  Onco Targets Ther       Date:  2019-07-25       Impact factor: 4.147

Review 7.  Rac1, A Potential Target for Tumor Therapy.

Authors:  Jiaxin Liang; Linda Oyang; Shan Rao; Yaqian Han; Xia Luo; Pin Yi; Jinguan Lin; Longzheng Xia; Jiaqi Hu; Shiming Tan; Lu Tang; Qing Pan; Yanyan Tang; Yujuan Zhou; Qianjin Liao
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

8.  The prognostic value of Tiam1 protein expression in head and neck squamous cell carcinoma: a retrospective study.

Authors:  Hang Yang; Yu-Chen Cai; Ye Cao; Ming Song; Xin An; Yi Xia; Jing Wei; Wen-Qi Jiang; Yan-Xia Shi
Journal:  Chin J Cancer       Date:  2015-09-14

9.  Expression of Tiam1 predicts lymph node metastasis and poor survival of lung adenocarcinoma patients.

Authors:  Shuguang Liu; Yumei Li; Wenjuan Qi; Yunfei Zhao; Aili Huang; Wenjie Sheng; Bin Lei; Peixin Lin; Haili Zhu; Wenxia Li; Hong Shen
Journal:  Diagn Pathol       Date:  2014-03-24       Impact factor: 2.644

10.  TIAM1 inhibits lung fibroblast differentiation in pulmonary fibrosis.

Authors:  Zhicheng Huang; Shuangyan Sun; Changliang Yang; Jun Zheng; Yingji Nan; Ruikun Zhao; Zhiguo Lang; Hang Li; Lixia Ma
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.